Merck & Co to expand in India, favourable IPR ruling encourages co to invest more
The Delhi High Court decision on its anti-diabetes drug Januvia is among the factors encouraging Merck to invest in India, global CEO Kenneth Frazier told ET.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Diabetes | Endocrinology | Januvia | Legislation | Merck | Pharmaceuticals